Alkem Laboratories Limited (ALKEM) Earnings Call Transcript & Summary
August 14, 2026
Earnings Call Speaker Segments
Operator
operatorGood day, everyone, and welcome to the Alkem Laboratories Limited Q1 FY27 earnings conference call, presented by Motilal Oswal Financial Services Limited. <<operator_script>> At this point, I'll turn the conference over to Mr. Tushar Manudhane with Motilal Oswal Financial Services Limited. Thank you, and the floor is yours, sir.
Tushar Manudhane
analystThank you, Yusuf. Apologies that the call began later than scheduled. Good evening, all, and a warm welcome to Alkem Laboratories' first quarter FY27 earnings call. Joining us from management are Mr. Sandeep Singh, Managing Director; Mr. Nitin Agarwal, CFO; and Ms. Purvi Shah, Head of Investor Relations. Purvi, over to you.
Purvi Shah
executiveThank you, Tushar, and a good evening to all of you. Speaking for Alkem Laboratories, I'm glad to welcome each of you to the earnings call for quarter one of FY27. We released our financial results today, along with the press release and investor presentation, earlier in the day; all of these have been filed with the stock exchanges and can also be found on our website. We hope you've had a chance to go through them. Before we proceed, please be reminded that this call is being recorded, and both the audio recording and the transcript will be posted on the stock exchanges and our website shortly after the call concludes. Kindly also note that certain forward-looking statements may feature in today's discussion, and such statements ought to be considered together with the risks and uncertainties tied to our business and the environment in which we operate. With that, I'd now like to turn the call over to our MD, Mr. Sandeep Singh, for his insights. Over to you, sir.
Sandeep Singh
executiveThank you, Purvi. Good evening, everyone, and thanks for being with us on this call. During the period we are reviewing, we kept executing our strategy without interruption. The operating environment is still dynamic, yet our attention has remained on the fundamentals: strengthening the core business, raising operational efficiency, and making selective investments in areas capable of supporting growth that is both sustainable and profitable. The progress we are achieving on these priorities encourages us. At the same time, we stay mindful of external challenges and keep a disciplined stance on capital allocation, costs, and risk management. I'll give you a brief walkthrough of the main developments and our outlook, and after that we'll be glad to take your questions and engage. As for the key highlights: revenue from operations came in at INR3,740 crores, with year-on-year growth of close to 11%. India sales stood at INR2,497 crores, growing 10.3% year-on-year. International sales reached INR 1,222 crores, up 16% year-on-year. EBITDA margin was 20.5%. That growth was 3.7% year-on-year. R&D expenses accounted for 4% of our total revenue. Profit before tax was more or less flattish — technically 1.8% of growth. And net profit saw a degrowth of 21.7%. That is purely because of taxation reasons, and I'm sure our CFO will deep dive into this later on.
Sandeep Singh
executiveBased on IQVIA data, the company posted 13.2% growth year-on-year, compared with the Indian pharmaceutical market's 12.2% increase. That works out to 100-basis point outperformance, exactly as we guided you earlier. The acute segment grew 12.3% against the IPM's 10.1%, a 220-basis point outperformance. The chronic segment grew 17.9% against the IPM's 15.4%, 250-basis point outperformance. We outperformed the IPM in seven key focus therapies. Anti-infectives grew 1.1 times the market. Gastro grew 1.2 times the market. Vitamins and minerals grew 1.4, pain 1.8 times, anti-diabetic 1.4, respiratory 1.6, and last but not least, derma 1.6. During the quarter, for the U.S. market, the company received five ANDA approvals. One of them was a tentative approval. Recently, our Daman facility has received an OAI status. We have already initiated comprehensive corrective and preventive actions and remain fully engaged with the regulator to address the observations. While this represents an important regulatory development, approved product supplies from the facility continue to the U.S. market without any interruption. With this, I open the floor for Q&A. Thank you.
Operator
operatorThank you so much. <<operator_script>> Our first question comes from Saion Mukherjee at Nomura. The line is yours — please go ahead.
Saion Mukherjee
analystGood evening. Sandeep, you talked about India growing faster than what IQVIA reports for the market. We've seen some pickup in growth rates, yes, but 10.3% is below what most of the pharma companies reporting so far have posted. Could you shed some light on the dynamics at play here? What do you believe is weighing on the growth rate in India, and is there anything that could help lift the growth rate in the quarters to come?
Sandeep Singh
executiveYeah. I think the growth rate in India is being pulled down somewhat by trade generics. Growth in trade generics was basically flat, maybe just slightly positive. And trade generics now make up a fairly meaningful portion of our domestic formulation business. So that's what's dragging it lower.
Saion Mukherjee
analystAll right. And on the branded side — how much did branded grow this quarter? Branded generic.
Sandeep Singh
executiveThe figure came in at 12%. That's 12%. And then 1 to 2.
Saion Mukherjee
analystAlright, Nitin — regarding the rise in costs. You had, I believe, given guidance earlier that employee costs and other expenses would be on the higher side. So could you indicate how much of that cost comes from CDMO med tech, which may not be contributing at this point — or, for that matter, could you speak to the EBITDA loss from these businesses in this quarter?
Nitin Agarwal
analystOkay, Saion. On employee cost — yes, growth came in above 16% for the quarter. There are two, three reasons behind that. First is definitely the annual increment. Second, we brought in roughly 1,200 MRs over the last few quarters, and that had an impact on employee cost as well. And the CDMO business at Enzene went operational starting November ’25. So that was the third factor affecting manpower. On other expenses — yes, there were costs related to the Enzene CDMO business. On top of that, the dollar conversion rate went up, which helped us on the top line, but it also hits other expenses, since all our subsidiaries — the foreign subsidiaries’ expenses got converted at a higher rate. That rate is almost 10% above last year’s. So those were the reasons. Med tech — yes, we have closed the Occlutech acquisition, but that happened in mid-July. So our quarter one numbers weren’t affected by Occlutech. Yes, the ortho business we acquired, but I think it’s small in scale. At the consolidated level, the impact isn’t that large. But just to share the numbers, yeah, there was — you could say, if we exclude the due diligence cost and all of Occlutech, there was an EBITDA loss of around INR5 crores, INR7 crores.
Nitin Agarwal
analystSince we're putting money into this business as well, and we're filing for our products outside India, this business will definitely break even, perhaps within the next 12 months — but the scale is small. At the yearly level, for instance, we'll do about INR50 crores of sales from the ortho business other than Occlutech.
Saion Mukherjee
analystAnd regarding the U.S. CDMO business, Nitin, what's the size of the drag coming from that?
Nitin Agarwal
analystIn the U.S., we're running about INR60 crores in operational expense. So this is definitely a new business. We're aiming to break even in the next, let's say, four to five quarters. But yes, for the quarter it came in at roughly INR60 crores, along those lines.
Saion Mukherjee
analystAlright, thanks.
Operator
operatorThanks. Our next question comes from Sandeep Kumar S. at Clindus. The line is yours — go ahead.
Sandeep Kumar
analystHi there. Thanks for asking. First off, where does the denosumab biosimilar currently stand in the U.S.?
Sandeep Singh
executiveYeah. So the denosumab biosimilar approval is running a bit behind. We didn't receive it on the goal date, so it's been pushed back by at least a few months.
Sandeep Kumar
analystAll right, so my next question concerns the EU region. With Osqay having just been approved, do you have particular target markets where you plan to launch first, or should we expect availability across the whole EU at the same time?
Sandeep Singh
executiveOkay, no, no — my apologies, I didn’t catch that correctly. You mean the denosumab Europe plan, is that right?
Sandeep Kumar
analystYeah. Okay. Yeah. Okay, about the Prolia biosimilar. So is it just certain —
Sandeep Singh
executiveRegarding Prolia?
Sandeep Kumar
analystProlia, yes.
Sandeep Singh
executiveAlright. Alright. Yeah, we do — yeah, the one you'd expect. So we're partnered with a company named Theramex. They're our partner on it. We aren't handling it ourselves directly. And as you're aware, it's highly competitive. So there are a great many players, even in Europe, same as in the U.S. So it won't be a particularly meaningful ramp-up for any single one of us for a while. So it isn't anything very significant. Yeah.
Sandeep Kumar
analystAll right, so my final question concerns the recent opinion on the XGEVA biosimilar. When might we expect that XGEVA biosimilar to launch in Europe?
Sandeep Singh
executiveWe might be just 3 months out.
Sandeep Kumar
analystThree months out. All right. Appreciate the update. Thanks.
Sandeep Singh
executiveAppreciate it.
Operator
operatorThanks. <<operator_script>> The next question comes from Amlan Jyoti Das at J.P. Morgan. Go ahead, please.
Amlan Jyoti Das
analystHello, sir. Sir, my question is about the India biosimilar —
Operator
operatorApologies for cutting in, Amlan, but we’re picking up some background noise on your line.
Amlan Jyoti Das
analystOkay, is everything good at this point?
Operator
operatorYes, go ahead, please.
Amlan Jyoti Das
analystYeah. Sir, my question is about the biosimilar side in India. You had around 6 to 7 biosimilars launched in India through the India entity. How has that portfolio performed over the — since it launched, and what has it contributed to India revenues as such?
Sandeep Singh
executiveYeah. Nitin, do you want to handle that one? You know that percentage better than I do.
Nitin Agarwal
analystAs you mentioned, we've already brought out seven products, and our yearly sales run at roughly INR150 crores. So I don't — I believe we've performed quite well, and thanks to that backward integration, margins on these products have improved as well at the consolidated level.
Amlan Jyoti Das
analystNitin, so does this revenue fall within your India revenues?
Nitin Agarwal
analystYeah. That's right.
Amlan Jyoti Das
analystAll right, moving on to Occlutech. Sir, given that you completed this deal in July of this year, what's your view on how the business overall will grow from here, and how do you expect margins to ramp up? I recall you guided toward margins reaching 10% in the near term. Does that guidance still stand?
Nitin Agarwal
analystLook, this year, the initial plan had been to finish the acquisition and begin integration at some point in the first quarter, but that ended up being pushed back. So we only wrapped up the acquisition in the middle of July, and integration has now begun. As a result, for roughly 8 and a half months this year, our target for Occlutech stands at about INR400 crores in sales, with EBITDA at break-even. Given the delays that occurred with integration, yes, it will come in somewhat below the guidance we provided previously.
Amlan Jyoti Das
analystAnd sir, looking forward, how should we view this margin over the next 2 to 3 years?
Nitin Agarwal
analystEach year, margins will improve steadily. As we mentioned at our investor meet, much of the integration with India operations begins kicking off next quarter. That said, you'll note — a 7% to 8% EBITDA improvement can be seen year-on-year. Our guidance is what we aim to hit across three to four years. Yes, but within, say, three to four years, it will be a very healthy EBITDA business for us.
Amlan Jyoti Das
analystOkay. And sir, last thing, if I can fit one more in. Regarding this OAI in the Daman unit, could you tell us what share of revenues from this unit goes to the U.S., if that figure is available?
Sandeep Singh
executiveMy understanding is that this facility accounts for 45% of the revenue we bring in from the U.S.
Amlan Jyoti Das
analystAnd sir, are all these revenues — or all these products — still in supply?
Sandeep Singh
executiveYeah, yeah, that's right. Yes, yes. 100%.
Amlan Jyoti Das
analystAll right, sir, thank you. That covers what I wanted to ask. Thanks.
Sandeep Singh
executiveThanks for joining us.
Operator
operatorThanks. The next question comes from Kunal Dhamesha at Macquarie. Go ahead.
Kunal Dhamesha
analystHello there. Thanks for giving me the chance to speak. Could you shed some light on the reasons the trade generic business isn't expanding? Is this a matter of industry dynamics, or is it something specific to the company?
Sandeep Singh
executiveI'd say it's a mix of the two. Competition has become really intense. You'll recall that four, five years back, few companies were eager to compete in this segment, but today plenty of large players have moved in. And there's an internal piece too, since with a large number the law of large numbers inevitably comes into play. We might be first or second in this segment, and we've also made our market practices a bit tighter, being somewhat stricter about days outstanding. So that's what's driving this. Nitin, go ahead.
Nitin Agarwal
analystYeah. When you look at the January to June quarter — that January to June period — we performed well where growth is concerned. But yes, between April and June, some strategic decisions were made regarding outstanding DSOs and so on. And we've also raised our prices somewhat due to higher API prices. So I think inventory levels in the market may have come down as well. So in the quarters ahead, primary sales, or the sales coming from this business, ought to recover. And as for the lower growth we saw in quarter one, I think growth in the coming quarters should be above that. So January to June, we did well in trade generic, if you look at the six-month figures.
Kunal Dhamesha
analystAnd sir, well, does that mean double-digit growth? How would you quantify that in some way?
Nitin Agarwal
analystIt was in the higher single digits.
Kunal Dhamesha
analystHigh single digit. All right. All right. And then what we're saying is that April through June was flat compared with a year earlier.
Nitin Agarwal
analystYeah, yeah.
Kunal Dhamesha
analystThat means January through March would have come in at a double-digit level.
Nitin Agarwal
analystYeah, that's fair to say.
Kunal Dhamesha
analystSecond, regarding the drag from the CDMO business of INR60 crores — that figure seems rather large. So really, what is it — is that an annual number or a quarterly one?
Nitin Agarwal
analystThis is something we do every quarter.
Sandeep Singh
executiveRight, that's a CDMO U.S. expense. Yeah.
Kunal Dhamesha
analystAll right, so if we're going to reach breakeven over the next 12 months, what level of revenue would we need to bring in? And then, when it comes to the project pipeline, do we have that visibility at this point?
Sandeep Singh
executiveNo, that's a fair question. Just so we're very clear, we won't break even over the next 12 months. For the U.S., we will not break even — that's number one. As for revenues, what we need is perhaps close to $20 million in order to break even.
Kunal Dhamesha
analystSorry, sir, I didn’t catch your figure. Was it $12 million?
Sandeep Singh
executiveNo, no — I meant $30 million. My mistake, I said $20 million, but the real figure is $30 million. Once we hit $25 million to $30 million, we break even there. Right.
Kunal Dhamesha
analystWas that per quarter?
Sandeep Singh
executiveNo, that’s on an annualized basis.
Kunal Dhamesha
analystOn an annualized basis. All right. All right. And on that point — since CDMO covers quite a broad spectrum, correct, so which portion are we going after first? Yes, that would be useful.
Sandeep Singh
executiveYeah. Since Enzene focuses on monoclonal antibodies, that's exactly it — we work solely with mAbs. We handle everything from development through to clinical trial supplies, and hopefully commercial production down the road. But as of now, these are mostly clinical trial batches and development batches.
Kunal Dhamesha
analystYeah, yeah. So, for that INR30 million run rate — how many projects would we need to be working on, roughly?
Sandeep Singh
executiveNo — so that's really all we have to go on. It depends, you could say. A few of these projects are quite big, so the count of projects isn't the thing. I'd say our pipeline is reasonably solid. The sales cycle for a CDMO differs greatly from what we've traditionally done in branded pharma. So I think patience will be needed on that side. And the cycle time is quite long, and working with these companies that could be innovators — not necessarily big pharma, even small biotech — they take their own time, and much rides on various factors: how well they get funded, how the clinical trial moves along. So I'd call it a mixed bag where patience would pay off. And just as I'm sure you follow a lot of CDMO companies, all of you know that. We can't measure it with the same tape we use for traditional Alkem pharma or any pharma. Still, we are positive, which is why we have put the facility in place.
Kunal Dhamesha
analystSure. And finally, sir, what kind of capacity do we have there? Is it mostly R&D-focused right now, and then down the line, would we need to make some sort of capital expenditure?
Sandeep Singh
executiveRight. So capacity-wise, we're in a reasonable spot. We're not especially large — our capacity is small — but our technology is somewhat distinct. So if I were to talk about KL specifically, that wouldn't truly reflect what we're able to produce there. And the second thing is, at a certain point, capex will need to take place there as we scale up, since absent that, we won't really achieve economies of scale — the same as with any API/CDMO or biotech business.
Kunal Dhamesha
analystSure. And —
Sandeep Singh
executiveYeah. That's not going to happen this year.
Kunal Dhamesha
analystAnd is this facility GMP compliant — as in, approved by the U.S. FDA?
Sandeep Singh
executiveRight, naturally. Since it isn’t approved by the U.S. FDA — that requires a trigger — but it’s definitely available in the U.S., and we’re collaborating with plenty of solid companies, and at some point we’ll need to trigger the U.S. FDA.
Kunal Dhamesha
analystAlright. That's going to happen with a few of the clients once they file, and so on.
Sandeep Singh
executiveYes. Definitely, sir.
Kunal Dhamesha
analystAlright, and the final question concerns the U.S. plant. We stated that the revenue contribution accounts for 45% of U.S.
Sandeep Singh
executiveRegarding Daman.
Kunal Dhamesha
analystYes, Daman. How many ANDAs are currently pending, and what is the total count of pending ANDAs at this moment?
Sandeep Singh
executiveRegarding Daman — we’ll return to that. We don’t have the precise figure right now. We’ll come back to it.
Kunal Dhamesha
analystAlright.
Sandeep Singh
executiveYeah.
Kunal Dhamesha
analystAlright.
Sandeep Singh
executiveOnce we’re able to come out, then fully.
Kunal Dhamesha
analystAll right.
Sandeep Singh
executiveYeah.
Kunal Dhamesha
analystThanks, and I wish you the very best.
Sandeep Singh
executiveAppreciate it.
Operator
operatorThank you. <<operator_script>> The next question comes from Kunal Randeria of Axis Capital. Kindly proceed.
Kunal Randeria
analystYeah, hello, and good afternoon. My first question concerns the India business. Last year, you entered orthopedics through a couple of small acquisitions. Will you still be looking to grow this business, or would you prefer to wait until perhaps a new CEO is named? You made a couple last year. In India. I'm just trying to restate my question.
Sandeep Singh
executiveAlright, my apologies — apologies. So regarding orthopedics, nothing has been acquired on our side. That falls under med tech. You mean medical tech — medical devices.
Kunal Randeria
analystNo, no, no. Not at all, sir. You had bought a couple of smaller companies, correct? Bombay Ortho and —
Sandeep Singh
executiveNo, sir, Bombay Ortho is a medical device — it's not prescription pharma.
Kunal Randeria
analystAlright, my apologies.
Sandeep Singh
executiveThat's not a pharmaceutical product.
Kunal Randeria
analystThat's my mistake. I apologize. Would you still be looking to expand into this, or would you rather wait for perhaps a new CEO to come aboard and then figure out how to expand?
Sandeep Singh
executiveNo, that depends. Right now we aren't looking to acquire anything in orthopedics or med tech. So that's the first thing. Yes. So whether or not to wait isn't really a question. It's very early, I think. The ramp-up is happening, and there's no need to acquire anything over there right now. Yes.
Kunal Randeria
analystRight, right, okay, sure. So, any plans? At this point we’re holding INR57 million in gross cash. Is there anything you’d like to share about plans?
Sandeep Singh
executiveNo, nothing at all. Everything remains just as it was. Nothing has changed since last quarter.
Kunal Randeria
analystAll right, understood. And just one final item. Are you going to be launching <<inaudible>> here in the U.S. during this quarter?
Sandeep Singh
executiveYes, that’s correct — we would.
Kunal Randeria
analystAlright, perfect sir. Thanks, and best of luck.
Sandeep Singh
executiveI appreciate that.
Operator
operatorThanks. Our next question comes from Abdulkader Puranwala at ICICI Securities. Please go ahead.
Abdulkader Puranwala
analystHello, and thanks for taking my question. First off, I'd like to ask about the trade generic business. I realize it was affected by your receivable policies, or your credit period. But, I mean, that segment has been expanding at a sluggish pace over the last couple of quarters. So is there any timeline you could share with us regarding when you expect growth in this particular segment to bounce back?
Sandeep Singh
executiveNo — what do you actually mean by bounce back? Like, what — how much do you figure we ought to be doing?
Abdulkader Puranwala
analystI'd say it should at minimum match the growth rate you're seeing in your branded pharma business.
Sandeep Singh
executiveNope, nope—that one’s really tough.
Abdulkader Puranwala
analystAll right, so that—
Sandeep Singh
executiveWe don’t want to see that. Beyond that, it comes down to discipline. We’ll need to reset it, and we’ll need to work things out. And we’ll watch how the market develops as well. So personally, as the promoter and MD, I would be — late single-digits makes me happy. That’s perfectly fine. What we really need in that business over the next one to two years is execution and discipline.
Nitin Agarwal
analystThe reason being that no capex is needed in that case. ROCE —
Sandeep Singh
executiveRight, ROCE looks solid — and yes, our CFO never lets me forget that point. So we need to stay cautious there. That's true.
Abdulkader Puranwala
analystOkay, sir, understood. And sir, my second question is about whether there are any thoughts on bringing in a CEO? I mean —
Sandeep Singh
executiveYes, yes. As we mentioned previously, we are searching. So our position remains unchanged, and ideally at the next quarterly meeting, he will be present alongside you. So we are searching, sir. As you are aware, this is a critical hire. We cannot rush it. But we are searching, sir. That is very clear. Yes.
Abdulkader Puranwala
analystUnderstood, sir. And just a few administrative questions, if I may. On the tax rate, I believe our guidance last quarter was 27% to 28%. For the full year, are we still holding to roughly that level?
Nitin Agarwal
analystYou see, that figure was for standalone, but when you look at consolidated level, it'll land somewhere around 30% to 32%, since a few of the entities — like our <<inaudible>> and others — are posting losses, and right now we aren't recognizing a deferred tax asset on those entities, which is why our consolidated tax rate appears somewhat higher than the standalone one. So on a consolidated basis, you're looking at somewhere in the 30% to 32% range.
Abdulkader Puranwala
analystGot it, sir. Thanks very much — and best of luck to you.
Operator
operatorThanks. <<operator_script>> The next question comes from Tushar Manudhane of Motilal Oswal. Please proceed.
Tushar Manudhane
analystYeah, thanks, Yusuf. Sir, regarding the India business, could you break out price, volume, and new launches growth for the quarter?
Nitin Agarwal
analystOn price, growth came in at roughly 6%. That figure excludes the trade generic business. New launches contributed about 3%, while volume added around 2%.
Tushar Manudhane
analystAnd sir, overall the industry’s growth rate has, I’d say, gotten somewhat better over the past few months. Have you noticed or experienced anything different that’s sort of pushing that growth, and how sustainable do you think those figures are when it comes to overall IPM growth, whether it’s chronic or acute?
Sandeep Singh
executiveNo, from our perspective, I don't think anything has shifted dramatically. Semaglutide has lost patent protection, I believe. So those sorts of factors are largely what's driving chronic, I'd say. And so we view whatever we're doing as quite sustainable, at least.
Tushar Manudhane
analystUnderstood. And what kind of benefit would Alkem Lab have gotten from semaglutide?
Sandeep Singh
executiveAt the moment it’s very small, sir. Yeah, small. Even so, in generics we rank among the top three. That much I can tell you.
Tushar Manudhane
analystUnderstood. And then, sir, a second question on the U.S. CDMO—those opex items, how should we think about them across the whole of ’27? Does the INR60 crores come first?
Sandeep Singh
executiveYes, you can look into that. Operating expenses are going to stay where they are. We’ll need to bring in business, and that’s the way we can reach break-even and ultimately turn a profit. We can’t reduce opex too heavily, because, you know, of how complex a U.S. plant is.
Tushar Manudhane
analystUnderstood, sir. So a few business opportunities were delayed, and that's the reason break-even is really dragging on a bit — or is this just how it's been tracking?
Sandeep Singh
executiveWell, I think it’s a mix of the two, because at times reality steps in and pushes things back. So I think we understood it would be costly and that business would be hard, but it’s taking longer than, say, 2 quarters to hit the numbers we were aiming for. And CDMO is a lumpy business too, as you know. So it’s the kind of thing where when it rains, it pours. Whenever it does come, it’ll come big, in our view.
Tushar Manudhane
analystUnderstood. The new contracts are likely in place, and that's where the work is focused. So there's some gestation period before we see the results from that.
Sandeep Singh
executiveYeah, definitely.
Tushar Manudhane
analystThanks. I really appreciate you taking my questions.
Sandeep Singh
executiveThanks for joining us.
Operator
operatorThanks. Our next question comes from Rashmi Shetty at Dolat Capital. You have the floor.
Rashmmi Shetty
analystThanks for taking the question. Sir, regarding the U.S., if we translate it into dollar terms, on a constant currency basis, we observed some softness in U.S. sales during the quarter. So if you could spell out what drove that, both year over year and quarter on quarter, as I’m seeing that. And previously we guided that for the full year, the U.S. would be in high single digits. So now, after this quarter, what’s your outlook? Also factoring in the Daman plant OAI.
Sandeep Singh
executiveOkay, I'll take the last question first. The Daman plant is something we're watching, but we don't believe it will affect our business, since nothing has halted and production has largely continued. So we're confident this year won't be affected. We also expect to get past this within six to 12 months, hopefully. So Daman shouldn't have any impact on the business this year. And on price — NRV erosion was roughly flat. So price erosion has more or less bottomed out, in our view, and perhaps for the industry too, though I'm not certain. So the U.S. is challenging. We really aren't seeing volume growth. It's mostly due to currency, and that remains a reality.
Nitin Agarwal
analystRegarding new products.
Sandeep Singh
executiveYeah.
Rashmmi Shetty
analystSo what you're saying is that for the products you launched over the last 12 to 24 months, you haven't really seen any significant volume growth?
Sandeep Singh
executiveI'd say that's right. That's a reasonable assumption. Yeah.
Rashmmi Shetty
analystAll right, so what's the outlook for the full year then? Are we still keeping — holding to our guidance of roughly high single digits? Or do you think it'll be flattish?
Sandeep Singh
executiveMy guess is that it lands somewhere between high single digits and the mid range.
Rashmmi Shetty
analystAlright, so, mid to high single digit.
Sandeep Singh
executiveRight, right. And currency is definitely going to give it a boost.
Rashmmi Shetty
analystAnd regarding that $30 million in revenue we expect from the CDMO business, when can we anticipate it — which year, and by when should we expect that revenue to start coming in?
Sandeep Singh
executive'27-'28.
Rashmmi Shetty
analystFiscal year 2028.
Sandeep Singh
executiveYes.
Rashmmi Shetty
analystAnd once more, looking at India overall — combining the trade generics operation with the branded formulations operation — what sort of growth should we be looking for across the full year?
Sandeep Singh
executiveRoughly in line with what we guided to previously, though we think we can improve on that by around 100 basis points.
Rashmmi Shetty
analystSo your sense is that in the quarters ahead, whatever growth we've lost in trade generics, we'll be able to make up for it, and branded formulation will keep performing. Is that a fair assumption?
Sandeep Singh
executiveYes. Yes. Yeah, we could end up by close to 12%. Yes.
Rashmmi Shetty
analystAlright. Appreciate it, sir. That covers everything on my end.
Sandeep Singh
executiveThanks for joining us.
Operator
operatorThanks. <<operator_script>> Our next follow-up comes from Amlan Jyoti Das at J.P. Morgan. The line is yours — please go ahead.
Amlan Jyoti Das
analystYeah. Thanks for the follow-up, sir. I recall that a couple of years back, in your annual report, you said you were putting all your focus on markets outside the U.S. and on international business. So has anything significant happened on that front? And this double-digit growth we're seeing — how sustainable do you think it is?
Sandeep Singh
executiveThis is quite sustainable—more than sustainable, actually. Yeah, we're seeing solid double-digit growth, and that's going to keep going.
Amlan Jyoti Das
analystSir, is there anything you'd like to highlight?
Sandeep Singh
executiveI mean, the thing is, the U.S. is so large that everything else, even with very high growth, really won't move the needle over the next few years. But some countries start from a low base and keep growing at very, very healthy double digits. They're on a small base, though. So Germany, for example, grows by 35%, 40%, but it's so small that I don't feel like talking about it too much. It might not be a good use of our time right now.
Nitin Agarwal
analystWe performed well in Chile and Australia too.
Sandeep Singh
executiveYeah, yeah.
Nitin Agarwal
analystChile and Australia are both significant markets for us, and we've been performing well.
Amlan Jyoti Das
analystAll right, sir. Sir, my final question concerns gross margins. This quarter showed an improvement in gross margins. So, sir, is there any specific reason behind that, and how do you expect those margins to hold up in the near term, in FY27 and ’28?
Nitin Agarwal
analystDuring the first quarter, there were three, four factors at play. First, as we already talked about, growth in our trade generic segment came in lower, while our prescription business performed quite strongly. There was also a currency effect, since the U.S. and other markets — even Australia as well — the currency worked in our favor. So on the whole, the mix improved for us thanks to the softer trade generic business, and the currency tailwind also gave us support. For the full year, we're keeping the same guidance, because some impact may come from API price increases, which we've already started to see. But because we held inventories, older inventories at older rates, the impact wasn't that large this quarter. In the quarters that follow, though, there will be an impact from API prices. So we're maintaining the same guidance of 66.5% to 67% gross margins for the balance of the year.
Amlan Jyoti Das
analystUnderstood, sir. Thanks, sir. Many thanks.
Operator
operatorThank you. Ladies and gentlemen, since no participants have any more questions, I'll now turn the conference back to management for their closing remarks.
Purvi Shah
executiveThanks, Yusuf, and thanks to all of you for being on today’s call. If you have any follow-up questions or need any clarification, please don’t hesitate to get in touch with us. Thank you. Enjoy the weekend too.
Operator
operator<<operator_signoff>>
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Alkem Laboratories Limited transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Alkem Laboratories Limited earnings transcripts and 131,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Alkem Laboratories Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.